MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other nootropic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.
1 . A method of stimulating or increasing neurogenesis in a cell or tissue, said method comprising
a) contacting said cell or tissue with a nootropic agent in combination with one or more other neurogenic agents, wherein the combination is effective to produce neurogenesis in said cell or tissue; or
b) contacting said cell or tissue with a nootropic agent, with the provision that said agent is not coluracetam, wherein the agent is effective to produce neurogenesis in said cell or tissue.
2 . The method of claim 1 , wherein said cell or tissue is in an animal subject or a human patient.
3 . The method of claim 2 , wherein said patient is in need of neurogenesis or has been diagnosed with a disease, condition, or injury of the central or peripheral nervous system.
4 . The method of claim 1 , wherein said nootropic agent is piracetam, FK-960, FK-962, or SGS-111.
5 . The method of claim 1 , wherein said neurogenesis comprises differentiation of neural stem cells (NSCs) along a neuronal lineage.
6 . The method of claim 1 , wherein said neurogenesis comprises differentiation of neural stem cells (NSCs) along a glial lineage.
7 . The method of claim 1 , wherein said nootropic agent is a racetam.
8 . The method of claim 2 , wherein said cell or tissue exhibits decreased neurogenesis or is subjected to an agent which decreases or inhibits neurogenesis.
9 . The method of claim 8 , wherein said agent which decreases or inhibits neurogenesis is an opioid receptor agonist.
10 . The method of claim 9 , wherein said opioid receptor agonist is morphine or another opiate.
11 . The method of claim 2 wherein said subject or patient has one or more chemical addiction or dependency.
12 . A method of treating a nervous system disorder related to cellular degeneration, a psychiatric condition, cellular trauma and/or injury, or another neurologically related condition in a subject or patient, said method comprising
a) administering a nootropic agent in combination with one or more other neurogenic agents, to produce an improvement in said disorder in said subject or patient; or
b) administering a nootropic agent, with the proviso that the agent is not coluracetam, to produce an improvement in said disorder in said subject or patient.
13 . The method of claim 12 , wherein said nervous system disorder related to cellular degeneration is selected from a neurodegenerative disorder, a neural stem cell disorder, a neural progenitor cell disorder, a degenerative disease of the retina, an ischemic disorder, and combinations thereof.
14 . The method of claim 12 , wherein said nervous system disorder related to a psychiatric condition is selected from a neuropsychiatric disorder, an affective disorder, depression, hypomania, panic attacks, anxiety, excessive elation, bipolar depression, bipolar disorder (manic-depression), seasonal mood (or affective) disorder, schizophrenia and other psychoses, lissencephaly syndrome, anxiety syndromes, anxiety disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behavior syndromes, borderline personality disorder, non-senile dementia, post-pain depression, post-partum depression, cerebral palsy, and combinations thereof.
15 . The method of claim 12 , wherein said nervous system disorder related to cellular trauma and/or injury is selected from neurological traumas and injuries, surgery related trauma and/or injury, retinal injury and trauma, injury related to epilepsy, spinal cord injury, brain injury, brain surgery, trauma related brain injury, trauma related to spinal cord injury, brain injury related to cancer treatment, spinal cord injury related to cancer treatment, brain injury related to infection, brain injury related to inflammation, spinal cord injury related to infection, spinal cord injury related to inflammation, brain injury related to environmental toxin, spinal cord injury related to environmental toxin, and combinations thereof.
16 . The method of claim 12 , wherein said neurologically related condition is selected from learning disorders, memory disorders, autism, attention deficit disorders, narcolepsy, sleep disorders, cognitive disorders, epilepsy, temporal lobe epilepsy, and combinations thereof.
17 . The method of claim 14 , wherein said psychiatric condition comprises depression.
18 . The method of claim 17 , wherein said one or more other neurogenic agents comprises an anti-depressant agent; or
wherein said depression is due to morphine, alcohol, or drug use by the subject or patient.
19 . The method of claim 12 , wherein said nootropic agent is piracetam, FK-960, FK-962, or SGS-111; or
wherein said nootropic agent is in a combination with an AMPA agonist; or
wherein said nootropic agent in combination with one or more other neurogenic agents, is in a pharmaceutically acceptable formulation.
20 . A method of preparing cells or tissue for transplantation to a subject or patient, said method comprising
a) contacting said cell or tissue with a nootropic agent in combination with one or more other neurogenic agents, to stimulate or increase neurogenesis in said cell or tissue; or
b) contacting said cell or tissue with a nootropic agent, with the proviso that the agent is not coluracetam, to stimulate or increase neurogenesis in said cell or tissue.